Back to results
US 11,028,160 B2Granted
Treating refractory migraine
AssigneeTeva Pharmaceuticals International GmbH
InventorsMarcelo Bigal, Ernesto Aycardi
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Claims30
A method of treating or preventing migraine in a subject having refractory migraine, the method comprising:
- selecting a subject who has been treated with two or more different classes of preventative migraine treatments wherein at least one of the classes of preventative migraine treatments is selected from the group consisting of beta-blockers, anticonvulsants, tricyclics, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, and valproates;
- and
- administering to the subject a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody comprising the amino acid sequence of the heavy chain variable region set forth in SEQ ID NO:
- 63 and the amino acid sequence of the light chain variable region set forth in SEQ ID NO:
- 62.
2 more elements
Dependencies are inferred from the claim text.